TSX: MFI
www.mapleleaffoods.com
Meat Protein delivers top-line growth of 5.0% and Adjusted EBITDA Margin of 7.6% in the quarter
Plant Protein progressing toward Adjusted EBITDA target of neutral or better in the latter half of 2023
MISSISSAUGA, ON, May 11, 2023 /CNW/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or "the Company") (TSX: MFI) today reported its financial results for the first quarter ended March 31, 2023.
"Although global pork markets continued in their dislocation during our first quarter as expected, we made excellent progress in important dimensions of this inflection point year," said Michael H. McCain, Executive Chair and CEO of Maple Leaf Foods. "Our supply chain has made exceptional progress back to full normalization, we have advanced our much-needed inflation pricing, we began taking advantage of our renewed access to the Chinese markets and continue to see strong performance across our brands."
"We have line of sight on being Adjusted EBITDA neutral in our plant protein business this year, and our world-leading London poultry plant start-up is going exceptionally well as it is now operating at a full single shift," stated Mr. McCain. "At this point, we have full conviction that once pork markets normalize we will meet or exceed our financial targets of 14-16% Adjusted EBITDA margins, all while continuing to advance our vision to be the most sustainable protein company on earth."
First Quarter 2023 Highlights
Outlook
(i) | Refer to the section titled Non-IFRS Financial Measures in this news release. |
Financial Highlights
As at or for the | ||||||
Measure(i) (Unaudited) | Three months ended March 31, | |||||
2023 | 2022 | Change | ||||
Sales | $ 1,174.9 | $ 1,126.6 | 4.3 % | |||
Net (Loss) Earnings | $ (57.7) | $ 13.7 | nm(iv) | |||
Basic (Loss) Earnings per Share | $ (0.48) | $ 0.11 | nm(iv) | |||
Adjusted Operating Earnings(ii) | $ 19.3 | $ 16.1 | 19.8 % | |||
Adjusted (Loss) Earnings per Share(ii) | $ (0.12) | $ 0.03 | nm(iv) | |||
Adjusted EBITDA - Meat Protein Group(ii) | $ 87.3 | $ 97.5 | (10.5) % | |||
Adjusted EBITDA - Plant Protein Group(ii) | $ (12.0) | $ (30.7) | 60.9 % | |||
Free Cash Flow(ii)(iii) | $ 12.4 | $ (99.7) | 112.4 % | |||
Construction Capital(ii) | $ 18.4 | $ 615.9 | (97.0) % | |||
Net Debt(ii) | $ (1,677.3) | $ (1,290.7) | 30.0 % | |||
(i) | All financial measures in millions of dollars except Basic and Adjusted Earnings per Share. |
(ii) | Refer to the section titled Non-IFRS Financial Measures in this news release. |
(iii) | Certain comparative figures have been restated to conform with current year presentation. |
(iv) | Not meaningful. |
Sales for the first quarter of 2023 were $1,174.9 million compared to $1,126.6 million last year, an increase of 4.3%, driven by higher sales in the Meat Protein Group more than offsetting a decrease in the Plant Protein Group. For more details on sales performance by operating segment, please refer to the section entitled Operating Review.
Net loss for the first quarter of 2023 was $57.7 million ($0.48 loss per basic share) compared to earnings of $13.7 million ($0.11 per basic share) last year. Net earnings were negatively impacted by results in the Meat Protein Group, driven by pork market headwinds, cost inflation, and higher start-up expenses, partly offset by pricing actions taken in prior quarters to mitigate inflation. These results were mitigated by stronger results in the Plant Protein Group with improved margins and lower Selling, General, and Administrative ("SG&A") spending as the segment continues to execute against its plan to be Adjusted EBITDA neutral in the latter half of 2023. In addition, results were negatively impacted by unrealized mark to market valuations on biological assets driven by changes in feed and hog markets, higher interest expense with increased rates and higher debt largely to fund strategic capital expenditures, partly offset by a tax recovery.
Adjusted Operating Earnings for the first quarter of 2023 were $19.3 million compared to $16.1 million last year, and Adjusted Earnings per Share for the first quarter of 2023 was a loss of $0.12 compared to earnings of $0.03 last year due to similar factors as noted above.
For further discussion on key metrics and a discussion of results by operating segment, refer to the section titled Operating Review.
Note: Several items are excluded from the discussions of underlying earnings performance as they are not representative of ongoing operational activities. Refer to the section entitled Non-IFRS Financial Measures at the end of this news release for a description and reconciliation of all non-IFRS financial measures. |
Operating Review
The Company has two reportable segments. These segments offer different products, with separate organizational structures, brands, and financial and marketing strategies. The Company's chief operating decision makers regularly review internal reports for these businesses. Performance of the Meat Protein Group is based on profitable revenue growth, Adjusted Operating Earnings and Adjusted EBITDA, while the performance of the Plant Protein Group in the short term is focused on obtaining Adjusted EBITDA neutral or better results.
The following table summarizes the Company's sales, gross profit (loss), SG&A, Adjusted Operating Earnings, Adjusted EBITDA, and Adjusted EBITDA Margin by operating segment for the three months ended March 31, 2023 and March 31, 2022.
Three months ended March 31, 2023 | Three months ended March 31, 2022 | |||||||
($ millions)(i) | Meat | Plant | Non- | Total | Meat | Plant | Non- | Total |
Sales | $ 1,143.9 | 37.4 | (6.4) | $ 1,174.9 | $ 1,089.4 | 44.9 | (7.7) | $ 1,126.6 |
Gross profit (loss) | $ 90.5 | (3.3) | (10.8) | $ 76.4 | $ 131.0 | (6.3) | 29.2 | $ 153.9 |
Selling, general and administrative expenses | $ 89.2 | 13.5 | — | $ 102.7 | $ 88.6 | 30.8 | — | $ 119.5 |
Adjusted Operating Earnings(iii) | $ 36.0 | (16.7) | — | $ 19.3 | $ 51.0 | (34.9) | — | $ 16.1 |
Adjusted EBITDA(iii) | $ 87.3 | (12.0) | — | $ 75.3 | $ 97.5 | (30.7) | — | $ 66.8 |
Adjusted EBITDA Margin(iii) | 7.6 % | (32.1) % | n/a | 6.4 % | 9.0 % | (68.4) % | n/a | 5.9 % |
(i) | Totals may not add due to rounding. |
(ii) | Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, changes in the fair value of biological assets and derivatives, and non-allocated costs which are comprised of expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results. |
(iii) | Refer to the section titled Non-IFRS Financial Measures in this news release. |
Meat Protein Group
The Meat Protein Group is comprised of prepared meats, ready-to-cook and ready-to-serve meals, snack kits, value-added fresh pork and poultry products that are sold to retail, foodservice and industrial channels, and agricultural operations in pork and poultry. The Meat Protein Group includes leading brands such as Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, and other leading regional brands.
Sales for the first quarter of 2023 increased 5.0% to $1,143.9 million compared to $1,089.4 million last year. Sales growth was driven by pricing action implemented in prior quarters to mitigate inflation, a favourable mix-shift in product sales, and favourable foreign exchange. These positive factors were partially offset by lower sales volumes.
Gross profit for the first quarter of 2023 was $90.5 million (gross margin of 7.9%) compared to $131.0 million (gross margin of 12.0%) last year. Gross profit was negatively impacted by pork market headwinds and cost inflation partially offset by pricing action to address inflation. Gross profit for the first quarter included start-up expenses of $34.8 million (2022: $8.7 million) associated with Construction Capital projects, which are excluded in the calculation of Adjusted Operating Earnings.
SG&A expenses for the first quarter of 2023 were $89.2 million compared to $88.6 million last year. The increase in SG&A expenses was driven by higher salaries and discretionary spend, partially offset by lower advertising and promotional expenses, primarily due to timing.
Adjusted Operating Earnings for the first quarter of 2023 were $36.0 million compared to $51.0 million last year, driven by factors noted above.
Adjusted EBITDA for the first quarter of 2023 were $87.3 million compared to $97.5 million last year, driven by factors consistent with those noted above. Adjusted EBITDA Margin for the first quarter was 7.6% compared to 9.0% last year, also driven by factors consistent with those noted above.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant protein products, premium grain-based protein, and vegan cheese products sold to retail, foodservice and industrial channels. The Plant Protein Group includes the leading brands Lightlife® and Field Roast™.
Sales for the first quarter of 2023 were $37.4 million compared to $44.9 million last year, representing a decrease of 16.7%, or 22.0% after excluding the impacts of foreign exchange driven by lower volumes in retail and foodservice products, partially offset by pricing action implemented in prior quarters to mitigate inflation.
Gross profit for the first quarter of 2023 was a loss of $3.3 million (gross margin loss of 8.7%) compared to a loss of $6.3 million (gross margin loss of 14.0%) last year. The improvement in gross margin was driven by pricing action to address inflation, operational improvements, and a reduction in start-up expenses, partially offset by the impact of lower sales volumes. Gross profit for the first quarter of 2022 included $2.2 million of start-up expense associated with Construction Capital projects which are excluded in the calculation of Adjusted Operating Earnings.
SG&A expenses for the first quarter of 2023 were $13.5 million (36.0% of sales) compared to $30.8 million (68.7% of sales) last year. The decrease in SG&A was largely driven by lower advertising and promotional expenses, as well as decreased consulting and headcount expenses.
Adjusted Operating Earnings for the first quarter of 2023 were a loss of $16.7 million compared to a loss of $34.9 million last year. The improvement in Adjusted Operating Earnings is consistent with the factors noted above.
Adjusted EBITDA for the first quarter of 2023 were a loss of $12.0 million compared to a loss of $30.7 million last year, driven by factors consistent with those noted above. Adjusted EBITDA Margin for the first quarter was a loss of 32.1% compared to a loss of 68.4% last year, also driven by factors consistent with those noted above.
Other Matters
On May 10, 2023, the Board of Directors approved a quarterly dividend of $0.21 per share (an increase of $0.01 per share from the 2022 first quarter dividends), $0.84 per share on an annual basis, payable June 30, 2023 to shareholders of record at the close of business June 8, 2023. Unless indicated otherwise by the Company at or before the time the dividend is paid, the dividend will be considered an eligible dividend for the purposes of the "Enhanced Dividend Tax Credit System".
Conference Call
A conference call will be held at 7:30 a.m. ET on May 11, 2023, to review Maple Leaf Foods' first quarter financial results. To participate in the call, please dial 416-764-8650 or 1-888-664-6383. For those unable to participate, playback will be made available an hour after the event at 416-764-8677 or 1-888-390-0541 (Passcode: 259164 #).
A webcast of the first quarter conference call will also be available at: https://www.mapleleaffoods.com
The Company's full consolidated interim financial statements ("Consolidated Interim Financial Statements") and related Management's Discussion and Analysis are available on the Company's website.
An investor presentation related to the Company's first quarter financial results is available at www.mapleleaffoods.com and can be found under Presentations and Webcasts on the Investors page.
Outlook
Maple Leaf Foods is a leading consumer protein company, supported by a portfolio of market leading brands. Over the last several years, the Company has developed a foundation to pursue compelling growth vectors across its business and to create value for all stakeholders.
Meat Protein Group
In Meat Protein, the Company's strategy is to drive profitable growth. Given the unprecedented market dynamics, marked by a challenging post-pandemic economy, the conflict in Europe, high inflation and significant market and supply chain disruption, Maple Leaf Foods expects that its Meat Protein Group will achieve the following:
Plant Protein Group
Capital
The ongoing effects of the post-pandemic economy induced supply chain disruptions and the war in Ukraine are unpredictable and may impact a number of factors that drive growth in the business, including:
The execution of the Company's financial and operational priorities are embedded in a commitment to deliver shared value for the benefit of all stakeholders. The Company's guiding pillars to be the "Most Sustainable Protein Company on Earth" include Better Food, Better Care, Better Communities, Better Planet and are core to how Maple Leaf Foods conducts itself. To that end, the Company's priorities include:
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA, Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash Flow and Return on Net Assets. Management believes that these non-IFRS measures provide useful information to investors in measuring the financial performance of the Company for the reasons outlined below. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS measures used by Management to evaluate financial operating results. Adjusted Operating Earnings is defined as earnings before other income, income taxes and interest expense adjusted for items that are not considered representative of ongoing operational activities of the business and certain items where the economic impact of the transactions will be reflected in earnings in future periods when the underlying asset is sold or transferred. Adjusted EBITDA is defined as Adjusted Operating Earnings plus depreciation and intangible asset amortization, adjusted for items included in other expense that are considered representative of ongoing operational activities of the business. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by sales.
The table below provides a reconciliation of earnings (loss) before income taxes as reported under IFRS in the Consolidated Interim Financial Statements to Adjusted Operating Earnings and Adjusted EBITDA for the three months ended March 31 as indicated below. Management believes that these non-IFRS measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements, including the Company's capital investment program.
Three months ended March 31, 2023 | Three months ended March 31, 2022 | |||||||
($ millions)(i) | Meat | Plant | Non- | Total | Meat | Plant | Non- | Total |
(Loss) earnings before income taxes | $ (3.5) | (21.4) | (45.0) | $ (69.9) | $ 37.8 | (37.1) | 20.4 | $ 21.0 |
Interest expense and other financing costs | — | — | 31.6 | 31.6 | — | — | 7.7 | 7.7 |
Other expense | 1.5 | 0.2 | 2.6 | 4.3 | 1.5 | — | 1.1 | 2.6 |
Restructuring and other related costs | 3.3 | 4.5 | — | 7.7 | 3.0 | — | — | 3.0 |
Earnings (loss) from operations | $ 1.3 | (16.7) | (10.8) | $ (26.3) | $ 42.3 | (37.1) | 29.2 | $ 34.4 |
Start-up expenses from Construction Capital(iii) | 34.8 | — | — | 34.8 | 8.7 | 2.2 | — | 10.9 |
Change in fair value of biological assets | — | — | 1.1 | 1.1 | — | — | (39.3) | (39.3) |
Unrealized loss on derivative contracts | — | — | 9.7 | 9.7 | — | — | 10.1 | 10.1 |
Adjusted Operating Earnings | $ 36.0 | (16.7) | — | $ 19.3 | $ 51.0 | (34.9) | — | $ 16.1 |
Depreciation and amortization | 52.7 | 4.9 | — | 57.7 | 48.0 | 4.2 | — | 52.3 |
Items included in other income (expense) representative of ongoing operations(iv) | (1.5) | (0.2) | — | (1.7) | (1.5) | — | — | (1.5) |
Adjusted EBITDA | $ 87.3 | (12.0) | — | $ 75.3 | $ 97.5 | (30.7) | — | $ 66.8 |
Adjusted EBITDA Margin | 7.6 % | (32.1) % | n/a | 6.4 % | 9.0 % | (68.4) % | n/a | 5.9 % |
(i) | Totals may not add due to rounding. |
(ii) | Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results. |
(iii) | Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production. |
(iv) | Primarily includes certain costs associated with sustainability projects, gains and losses on the sale of long-term assets, legal settlements, and other miscellaneous expenses. |
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by Management to evaluate financial operating results. It is defined as basic earnings per share and is adjusted on the same basis as Adjusted Operating Earnings. The table below provides a reconciliation of basic earnings per share as reported under IFRS in the Consolidated Interim Financial Statements to Adjusted Earnings per Share for the three months ended March 31 as indicated below. Management believes this basis is the most appropriate on which to evaluate financial results as they are representative of the ongoing operations of the Company.
($ per share) (Unaudited) | Three months ended March 31, | |||
2023 | 2022 | |||
Basic (loss) earnings per share | $ (0.48) | $ 0.11 | ||
Restructuring and other related costs(i) | 0.06 | 0.02 | ||
Items included in other expense not considered representative of ongoing operations(ii) | 0.02 | 0.01 | ||
Start-up expenses from Construction Capital(iii) | 0.21 | 0.07 | ||
Change in fair value of biological assets | 0.01 | (0.24) | ||
Change in unrealized fair value on derivatives | 0.06 | 0.06 | ||
Adjusted Earnings per Share(iv) | $ (0.12) | $ 0.03 | ||
(i) | Includes per share impact of restructuring and other related costs, net of tax. |
(ii) | Primarily includes legal fees, gains or losses on investment property, and transaction related costs, net of tax. |
(iii) | Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production. |
(iv) | Totals may not add due to rounding. |
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management to evaluate the amount of capital resources invested in specific strategic development projects that are not yet operational. It is defined as investments and related financing charges in projects over $50.0 million that are related to longer-term strategic initiatives, with no returns expected for at least 12 months from commencement of construction and the asset is re-categorized from Construction Capital once operational. The current balance of Construction Capital includes investment in increased further processed poultry capacity in the Prepared Meats facility in Brampton, Ontario. Investments in capacity at the Walker Drive facility in Brampton, Ontario, and the plant protein facility in Indianapolis, Indiana were moved out of construction capital upon completion during the first quarter of 2022, and the London Poultry facility was moved out of construction capital during the fourth quarter of 2022 when commercial production began. The following table is a summary of Construction Capital activity and debt financing for the periods indicated below.
($ thousands) (Unaudited) | 2023 | 2022 | ||
Property and equipment and intangibles at January 1 | $ 2,663,985 | $ 2,554,483 | ||
Other capital and intangible assets at January 1(i) | 2,654,419 | 1,811,164 | ||
Construction Capital at January 1 | $ 9,566 | $ 743,319 | ||
Additions | 8,822 | 54,776 | ||
Transfers from Construction Capital | — | (182,210) | ||
Construction Capital at March 31(ii) | $ 18,388 | $ 615,885 | ||
Other capital and intangible assets at March 31(i) | 2,635,039 | 1,975,946 | ||
Property and equipment and Intangibles at March 31 | $ 2,653,427 | $ 2,591,831 | ||
Construction Capital debt financing(iii)(iv) | $ 18,093 | $ 592,879 |
(i) | Other capital and intangible assets consists of property and equipment and intangibles that do not meet the definition of Construction Capital. |
(ii) | As at March 31, 2023, the net book value of Construction Capital includes $0.2 million related to intangible assets (March 31, 2022: $2.1 million; December 31, 2022: $0.0 million). |
(iii) | Does not include $1,008.0 million in capital that has been transferred out but is still in the start-up stage (2022: $202.8 million). |
(iv) | Assumed to be fully funded by debt to the extent that the Company has Net Debt outstanding. Construction Capital debt financing excludes interest paid and capitalized. |
Net Debt
The following table reconciles Net Debt to amounts reported under IFRS in the Company's Consolidated Interim Financial Statements as at March 31 as indicated below. The Company calculates Net Debt as cash and cash equivalents, less long-term debt and bank indebtedness. Management believes this measure is useful in assessing the amount of financial leverage employed.
($ thousands) (Unaudited) | As at March 31, | |||
2023 | 2022 | |||
Cash and cash equivalents | $ 79,433 | $ 66,476 | ||
Current portion of long-term debt | $ (1,130) | $ (5,220) | ||
Long-term debt | (1,755,560) | (1,351,992) | ||
Total debt | $ (1,756,690) | $ (1,357,212) | ||
Net Debt | $ (1,677,257) | $ (1,290,736) | ||
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to evaluate cash flow after investing in the maintenance of the Company's asset base. It is defined as cash provided by operations, less Maintenance Capital(i) and associated interest paid and capitalized. The following table calculates Free Cash Flow for the periods indicated below:
($ thousands) (Unaudited) | Three months ended March 31, | |||
2023 | 2022 | |||
Cash provided by (used in) operating activities | $ 35,714 | $ (84,993) | ||
Maintenance Capital(i) | (23,107) | (14,534) | ||
Interest paid and capitalized related to Maintenance Capital | (234) | (171) | ||
Free Cash Flow(ii) | $ 12,373 | $ (99,698) | ||
(i) | Maintenance Capital is defined as non-discretionary investment required to maintain the Company's existing operations and competitive position. Total capital spending of $49.3 million (2022: $97.3 million) shown on the Consolidated Statements of Cash Flows is made up of Maintenance Capital of $23.1 million (2022: $14.5 million), and Growth Capital of $26.2 million (2022: $82.8 million).Growth Capital is defined as discretionary investment meant to create stakeholder value through initiatives that for example, expand margins, increase capacities or create further competitive advantage. |
(ii) | Certain comparative figures have been restated to conform with current year presentation. |
Return on Net Assets ("RONA")
RONA is calculated by dividing tax effected earnings from operations (adjusted for items which are not considered representative of the underlying operations of the business) by average monthly net assets. Net assets are defined as total assets (excluding cash and deferred tax assets) less non-interest bearing liabilities (excluding deferred tax liabilities). Management believes that RONA is an appropriate basis upon which to evaluate long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written public communications often contain, "forward-looking information" within the meaning of applicable securities law. These statements are based on current expectations, estimates, projections, beliefs, judgements and assumptions based on information available at the time the applicable forward-looking statement was made and in light of the Company's experience combined with its perception of historical trends. Such statements include, but are not limited to, statements with respect to objectives and goals, in addition to statements with respect to beliefs, plans, targets, goals, objectives, expectations, anticipations, estimates, and intentions. Forward-looking statements are typically identified by words such as "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "could", "would", "believe", "plan", "intend", "design", "target", "undertake", "view", "indicate", "maintain", "explore", "entail", "schedule", "objective", "strategy", "likely", "potential", "outlook", "aim", "propose", "goal", and similar expressions suggesting future events or future performance. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes the expectations reflected in the forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon.
Specific forward-looking information in this document may include, but is not limited to, statements with respect to:
Various factors or assumptions are typically applied by the Company in drawing conclusions or making the forecasts, projections, predictions or estimations set out in the forward-looking statements. These factors and assumptions are based on information currently available to the Company, including information obtained by the Company from third-party sources and include but are not limited to the following:
Readers are cautioned that these assumptions may prove to be incorrect in whole or in part. The Company's actual results may differ materially from those anticipated in any forward-looking statements.
Factors that could cause actual results or outcomes to differ materially from the results expressed, implied, or projected in the forward-looking statements contained in this document include, among other things, risks associated with the following:
The Company cautions readers that the foregoing list of factors is not exhaustive.
Readers are further cautioned that some of the forward-looking information, such as statements concerning future capital expenditures, Adjusted EBITDA Margin growth in the Meat Protein Group, and Adjusted EBITDA target in the Plant Protein Group (including the timing, pace and impact of restructuring activities), may be considered to be financial outlooks for purposes of applicable securities legislation. These financial outlooks are presented to evaluate potential future earnings and anticipated future uses of cash flows and may not be appropriate for other purposes. Readers should not assume these financial outlooks will be achieved.
More information about risk factors can be found under the heading "Risk Factors" in the Company's Annual Management's Discussion and Analysis for the year ended December 31, 2022, that is available on SEDAR at www.sedar.com. The reader should review such section in detail. Additional information concerning the Company, including the Company's Annual Information Form, is available on SEDAR at www.sedar.com.
All forward-looking statements included herein speak only as of the date hereof. Unless required by law, the Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained herein are expressly qualified by this cautionary statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral company with a vision to be the most sustainable protein company on earth, responsibly producing food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™. The Company employs approximately 14,000 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in Mississauga, Ontario and its shares trade on the Toronto Stock Exchange (MFI).
Consolidated Interim Balance Sheets
(In thousands of Canadian dollars) | As at March 31, | As at March 31, | As at December 31, | As at January 1, | ||||
ASSETS | ||||||||
Cash and cash equivalents | $ 79,433 | $ 66,476 | $ 91,076 | $ 162,031 | ||||
Accounts receivable | 160,290 | 195,662 | 167,611 | 167,082 | ||||
Notes receivable | 35,506 | 55,016 | 48,556 | 33,294 | ||||
Inventories | 576,183 | 491,443 | 485,979 | 409,677 | ||||
Biological assets | 140,100 | 176,102 | 144,169 | 138,209 | ||||
Income taxes recoverable | 66,977 | 2,388 | 57,497 | 1,830 | ||||
Prepaid expenses and other assets | 47,004 | 42,155 | 50,266 | 24,988 | ||||
Assets held for sale | 11,204 | — | 604 | — | ||||
Total current assets | $ 1,116,697 | $ 1,029,242 | $ 1,045,758 | $ 937,111 | ||||
Property and equipment | 2,297,130 | 2,232,105 | 2,303,424 | 2,189,165 | ||||
Right-of-use assets | 155,140 | 165,080 | 159,199 | 161,662 | ||||
Investments | 23,656 | 22,085 | 23,712 | 22,326 | ||||
Investment property | 5,289 | 5,289 | 5,289 | 5,289 | ||||
Employee benefits | 16,599 | 25,709 | 12,531 | — | ||||
Other long-term assets | 9,223 | 14,619 | 12,493 | 9,780 | ||||
Deferred tax asset | 42,525 | 46,920 | 42,541 | 39,907 | ||||
Goodwill | 477,353 | 656,420 | 477,353 | 658,673 | ||||
Intangible assets | 356,297 | 359,726 | 360,561 | 365,318 | ||||
Total long-term assets | $ 3,383,212 | $ 3,527,953 | $ 3,397,103 | $ 3,452,120 | ||||
Total assets | $ 4,499,909 | $ 4,557,195 | $ 4,442,861 | $ 4,389,231 | ||||
LIABILITIES AND EQUITY | ||||||||
Accounts payable and accruals | $ 605,777 | $ 561,782 | $ 485,114 | $ 526,189 | ||||
Current portion of provisions | 36,114 | 8,812 | 42,589 | 842 | ||||
Current portion of long-term debt | 1,130 | 5,220 | 921 | 5,176 | ||||
Current portion of lease obligations | 37,349 | 38,176 | 38,321 | 31,375 | ||||
Income taxes payable | 1,100 | — | 2,311 | 23,853 | ||||
Other current liabilities | 42,533 | 49,601 | 64,684 | 81,265 | ||||
Total current liabilities | $ 724,003 | $ 663,591 | $ 633,940 | $ 668,700 | ||||
Long-term debt | 1,755,560 | 1,351,992 | 1,709,493 | 1,247,073 | ||||
Lease obligations | 140,304 | 147,592 | 144,569 | 144,391 | ||||
Employee benefits | 65,966 | 73,539 | 64,280 | 97,629 | ||||
Provisions | 3,631 | 38,336 | 3,799 | 44,650 | ||||
Other long-term liabilities | 2,197 | 4,988 | 1,841 | 1,057 | ||||
Deferred tax liability | 218,903 | 180,330 | 221,606 | 147,060 | ||||
Total long-term liabilities | $ 2,186,561 | $ 1,796,777 | $ 2,145,588 | $ 1,681,860 | ||||
Total liabilities | $ 2,910,564 | $ 2,460,368 | $ 2,779,528 | $ 2,350,560 | ||||
Shareholders' equity | ||||||||
Share capital | $ 850,616 | $ 859,396 | $ 850,086 | $ 847,016 | ||||
Retained earnings | 728,477 | 1,239,959 | 809,616 | 1,212,244 | ||||
Contributed surplus | 3,047 | 16,879 | — | 5,371 | ||||
Accumulated other comprehensive | 33,121 | 6,839 | 29,547 | 286 | ||||
Treasury stock | (25,916) | (26,246) | (25,916) | (26,246) | ||||
Total shareholders' equity | $ 1,589,345 | $ 2,096,827 | $ 1,663,333 | $ 2,038,671 | ||||
Total liabilities and equity | $ 4,499,909 | $ 4,557,195 | $ 4,442,861 | $ 4,389,231 | ||||
(i) | Restated, refer to Note 3 of the Consolidated Interim Financial Statements. |
Consolidated Interim Statements of Net (Loss) Earnings
(In thousands of Canadian dollars, except share amounts) (Unaudited) | Three months ended March 31, | |||
2023 | 2022 | |||
Sales | $ 1,174,889 | $ 1,126,553 | ||
Cost of goods sold | 1,098,442 | 972,690 | ||
Gross profit | $ 76,447 | $ 153,863 | ||
Selling, general and administrative expenses | 102,713 | 119,457 | ||
(Loss) earnings before the following: | $ (26,266) | $ 34,406 | ||
Restructuring and other related costs | 7,749 | 3,018 | ||
Other expense | 4,295 | 2,624 | ||
(Loss) earnings before interest and income taxes | $ (38,310) | $ 28,764 | ||
Interest expense and other financing costs | 31,603 | 7,716 | ||
(Loss) earnings before income taxes | $ (69,913) | $ 21,048 | ||
Income tax (recovery) expense | (12,209) | 7,361 | ||
Net (loss) earnings | $ (57,704) | $ 13,687 | ||
(Loss) earnings per share attributable to common shareholders: | ||||
Basic (loss) earnings per share | $ (0.48) | $ 0.11 | ||
Diluted (loss) earnings per share | $ (0.48) | $ 0.11 | ||
Weighted average number of shares (millions): | ||||
Basic | 121.3 | 124.0 | ||
Diluted | 121.3 | 126.1 | ||
Consolidated Interim Statements of Other Comprehensive Income (Loss)
(In thousands of Canadian dollars) (Unaudited) | Three months ended March 31, | |||
2023 | 2022 | |||
Net (loss) earnings | $ (57,704) | $ 13,687 | ||
Other comprehensive income | ||||
Actuarial (losses) gains that will not be reclassified to profit or loss (Net of tax of $0.7 million; | $ 2,124 | $ 38,901 | ||
Change in revaluation surplus (Net of tax of $1.7 million; 2022: $0.0 million) | 6,993 | — | ||
Total items that will not be reclassified to profit or loss | $ 9,117 | $ 38,901 | ||
Items that are or may be reclassified subsequently to profit or loss: | ||||
Change in accumulated foreign currency translation adjustment (Net of tax of $0.0 million; | (433) | (6,973) | ||
Change in foreign exchange on long-term debt designated as a net investment hedge | 119 | 3,561 | ||
Change in cash flow hedges (Net of tax of $1.1 million; 2022: $3.4 million) | (3,105) | 9,965 | ||
Total items that are or may be reclassified subsequently to profit or loss | $ (3,419) | $ 6,553 | ||
Total other comprehensive income | $ 5,698 | $ 45,454 | ||
Comprehensive (loss) income | $ (52,006) | $ 59,141 | ||
Consolidated Interim Statements of Changes in Total Equity
Accumulated other comprehensive income (loss) | |||||||||
(In thousands of Canadian dollars) (Unaudited) | Share capital | Retained earnings | Contributed surplus | Foreign | Unrealized | Unrealized | Revaluation | Treasury stock | Total equity |
Balance at December 31, 2022(iii) | $ 850,086 | 809,616 | — | 10,972 | 12,885 | 2,945 | 2,745 | (25,916) | $ 1,663,333 |
Net loss | — | (57,704) | — | — | — | — | — | — | (57,704) |
Other comprehensive income | — | 2,124 | — | (314) | (3,105) | — | 6,993 | — | 5,698 |
Dividends declared ($0.21 per | — | (25,559) | — | — | — | — | — | — | (25,559) |
Share-based compensation | — | — | 2,012 | — | — | — | — | — | 2,012 |
Deferred taxes on share- | — | — | 800 | — | — | — | — | — | 800 |
Exercise of stock options | 769 | — | — | — | — | — | — | — | 769 |
Shares re-purchased | (2,931) | — | (7,838) | — | — | — | — | — | (10,769) |
Change in obligation for | 2,692 | — | 8,073 | — | — | — | — | — | 10,765 |
Balance at March 31, 2023 | $ 850,616 | 728,477 | 3,047 | 10,658 | 9,780 | 2,945 | 9,738 | (25,916) | $ 1,589,345 |
Accumulated other comprehensive income (loss)(i) | |||||||||
(In thousands of Canadian dollars) (Unaudited) | Share capital | Retained earnings | Contributed surplus | Foreign | Unrealized | Unrealized | Revaluation | Treasury stock | Total equity |
Balance at January 1, 2022(iii) | $ 847,016 | 1,212,244 | 5,371 | 2,037 | (7,441) | 2,945 | 2,745 | (26,246) | $ 2,038,671 |
Net earnings | — | 13,687 | — | — | — | — | — | — | 13,687 |
Other comprehensive income | — | 38,901 | — | (3,412) | 9,965 | — | — | — | 45,454 |
Dividends declared ($0.20 per | — | (24,873) | — | — | — | — | — | — | (24,873) |
Share-based compensation | — | — | 4,396 | — | — | — | — | — | 4,396 |
Modification of stock | — | — | (3,594) | — | — | — | — | — | (3,594) |
Exercise of stock options | 3,718 | — | — | — | — | — | — | — | 3,718 |
Change in obligation for | 8,662 | — | 10,706 | — | — | — | — | — | 19,368 |
Balance at March 31, 2022 | $ 859,396 | 1,239,959 | 16,879 | (1,375) | 2,524 | 2,945 | 2,745 | (26,246) | $ 2,096,827 |
(i) | Items that are or may be subsequently reclassified to profit or loss. |
(ii) | Included in other comprehensive income (loss) is the change in actuarial gains and losses that will not be reclassified to profit or loss and has been reclassified to retained earnings. |
(iii) | Restated, refer to Note 3 of the Consolidated Interim Financial Statements. |
Consolidated Interim Statements of Cash Flows
(In thousands of Canadian dollars) (Unaudited) | Three months ended March 31, | |||
2023 | 2022 | |||
CASH PROVIDED BY (USED IN): | ||||
Operating activities | ||||
Net (loss) earnings | $ (57,704) | $ 13,687 | ||
Add (deduct) items not affecting cash: | ||||
Change in fair value of biological assets | 1,127 | (39,311) | ||
Depreciation and amortization | 67,425 | 57,191 | ||
Share-based compensation | 2,012 | 4,396 | ||
Deferred income taxes | (2,874) | 7,972 | ||
Income tax current | (9,335) | (611) | ||
Interest expense and other financing costs | 31,603 | 7,716 | ||
Loss on sale of long-term assets | 234 | 458 | ||
Change in fair value of non-designated derivatives | 3,109 | 1,574 | ||
Change in net pension obligation | 467 | 2,498 | ||
Net income taxes paid | (1,777) | (23,612) | ||
Interest paid, net of capitalized interest | (33,790) | (7,676) | ||
Change in provision for restructuring and other related costs | (6,006) | 1,713 | ||
Change in derivatives margin | (13,740) | (25,103) | ||
Cash settlement of derivatives | 11,009 | — | ||
Other | 217 | (1,251) | ||
Change in non-cash operating working capital | 43,737 | (84,634) | ||
Cash provided by (used in) operating activities | $ 35,714 | $ (84,993) | ||
Investing activities | ||||
Additions to long-term assets | $ (49,252) | $ (97,305) | ||
Interest paid and capitalized | (481) | (4,497) | ||
Proceeds from sale of long-term assets | 64 | 94 | ||
Cash used in investing activities | $ (49,669) | $ (101,708) | ||
Financing activities | ||||
Dividends paid | $ (25,559) | $ (24,873) | ||
Net increase in long-term debt | 48,800 | 114,862 | ||
Payment of lease obligation | (9,918) | (9,408) | ||
Receipt of lease inducement | — | 6,847 | ||
Exercise of stock options | 769 | 3,718 | ||
Repurchase of shares | (10,769) | — | ||
Payment of financing fees | (1,011) | — | ||
Cash provided by financing activities | $ 2,312 | $ 91,146 | ||
Decrease in cash and cash equivalents | $ (11,643) | $ (95,555) | ||
Cash and cash equivalents, beginning of period | 91,076 | 162,031 | ||
Cash and cash equivalents, end of period | $ 79,433 | $ 66,476 | ||
SOURCE Maple Leaf Foods Inc.
